Gail A.M. Cresci

Dr. Gail A.M. Cresci

Lerner Research Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
MSMohamed Tausif Siddiqui
Mohamed Tausif Siddiqui
GCGail A.M. Cresci
Gail A.M. Cresci
The gastrointestinal (GI) system contains many different types of immune cells, making it a key immune organ system in the human body. In the last decade, our knowledge has substantially expanded regarding our understanding of the gut microbiome and its complex interaction with the gut immune system. Short chain fatty acids (SCFA), and specifically butyrate, play an important role in mediating the effects of the gut microbiome on local and systemic immunity. Gut microbial alterations and depletion of luminal butyrate have been well documented in the literature for a number of systemic and GI inflammatory disorders. Although a substantial knowledge gap exists requiring the need for further investigations to determine cause and effect, there is heightened interest in developing immunomodulatory therapies by means of reprogramming of gut microbiome or by supplementing its beneficial metabolites, such as butyrate. In the current review, we discuss the role of endogenous butyrate in the inflammatory response and maintaining immune homeostasis within the intestine. We also present the experimental models and human studies which explore therapeutic potential of butyrate supplementation in inflammatory conditions associated with butyrate depletion.

8 October 2015 in Nutrition in Clinical Practice
Verified
Journal Article
Closed access
PDF file
GCGail A.M. Cresci
Gail A.M. Cresci
EBEmmy Bawden
Emmy Bawden

14 January 2017 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
GCGail A.M. Cresci
Gail A.M. Cresci
BGBryan Glueck
Bryan Glueck
MMMegan R McMullen
Megan R McMullen
WXWei Xin
Wei Xin
DADaniella Allende
Daniella Allende
LNLaura E Nagy
Laura E Nagy

24 April 2020 in Nutrition in Clinical Practice
Verified
Journal Article
Closed access
PDF file
FRFatemeh Ramezani
Fatemeh Ramezani
GCGail A.M. Cresci
Gail A.M. Cresci

1 April 2011 in Nutrition in Clinical Practice
Verified
Journal Article
Closed access
JWJeremy Warren
Jeremy Warren
VBVarun Bhalla
Varun Bhalla
GCGail A.M. Cresci
Gail A.M. Cresci

5 January 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
SRSANJOY ROYCHOWDURY
SANJOY ROYCHOWDURY
BGBryan Glueck
Bryan Glueck
YHYingchun Han
Yingchun Han
MMMahmoud Mohammad
Mahmoud Mohammad
GCGail A.M. Cresci
Gail A.M. Cresci
Gut dysbiosis and altered short-chain fatty acids are associated with ethanol-induced liver injury. SCFA are fermentation byproducts of the gut microbiota known to have many beneficial biological effects. We tested if a designer synbiotic could protect against ethanol-induced gut-liver injury. C57BL/6 female mice were exposed to chronic-binge ethanol feeding consisting of ethanol (5% vol/vol) for 10 days, followed by a single gavage (5 g/kg body weight) 6 h before euthanasia. A group of mice also received oral supplementation daily with a designer synbiotic, and another group received fecal slurry (FS); control animals received saline. Control mice were isocalorically substituted maltose dextran for ethanol over the entire exposure period. Ethanol exposure reduced expression of tight junction proteins in the proximal colon and induced hepatocyte injury and steatosis. Synbiotic supplementation not only mitigated losses in tight junction protein expression, but also prevented ethanol-induced steatosis and hepatocyte injury. Ethanol exposure also increased hepatic inflammation and oxidative stress, which was also attenuated by synbiotic supplementation. Mice receiving FS were not protected from ethanol-induced liver injury or steatosis. Results were associated with luminal SCFA levels and SCFA transporter expression in the proximal colon and liver. These results indicate supplementation with a designer synbiotic is effective in attenuating chronic-binge ethanol-induced gut-liver injury and steatosis in mice, and highlight the beneficial effects of the gut microbial fermentation byproducts.